shiseido co ltd (SSDOF) Snapshot

RepliCel Life Sciences Inc. and Shiseido Company, Limited announced that they have entered into a Collaboration and Technology Development Transfer Framework Agreement for an exclusive geographic license for RepliCel's RCH-01 hair regeneration technology. The Agreement will ultimately see further human clinical trials being conducted by Shiseido in its territory. In addition, the Agreement anticipates ongoing research collaboration for the continued improvement of the technology. RCH-01 is a patented hair follicle cell replication and implantation technology designed to rejuvenate damaged, miniaturized hair follicles in balding scalp skin. This technology has been developed over ten years of research, experimentation and trials. The mechanics of this technology involve the extraction of as few as 20 hair follicles from the back of a patient's scalp where healthy cycling hair follicles reside. Specific cells are isolated from the hair follicles and are then replicated in a current Good Manufacturing Practice compliant facility through the company's proprietary cellular replication process, and are then reintroduced back into balding areas on a patient's scalp. The implanted cells are expected to rejuvenate damaged hair follicles leading to the growth of new healthy hair fibers.

Shiseido Company, Limited, 2013 Earnings Call, Apr 26, 2013

Shiseido Company, Limited announced that they will report fiscal year 2013 results on Apr 26, 2013